The increasing adoption of drug of abuse (DOA) testing at the organizational level, growing number of road accidents and deaths, and rising consumption of illicit drugs are some of the reasons behind the growth of the DOA testing market. In 2016, the market generated a revenue of $4.8 billion, and it is predicted to advance at a CAGR of 9.6% during the forecast period (2017–2023). Drug testing refers to the technical analysis of sweat, blood, saliva, urine, breath, and hair samples to detect the presence of cocaine, cannabis, and alcohol.
Based on product, the drug of abuse testing market is bifurcated into consumable and equipment. Of these, during the historical period (2013–2016), the consumable bifurcation led the market in terms of revenue, and it is predicted to continue leading it during the forecast period. The reason behind the rapid growth of consumables is that these are handy and available for on-site testing for various types of drugs. Consumables include products such as rapid test kits that are used for the testing of illicit drugs.
To improve safety, increase productivity, and reduce absenteeism, organizations are rapidly adopting DOA testing at the workplace. As per the Substance Abuse and Mental Health Services Administration, in 2015, the hospitality and food services sector displayed the heaviest use of illicit drugs, and around 19.1% fulltime workers, aged between 18 and 64 years, in the U.S. were reported as consuming illicit drugs in a span of 30 days during 2008–2012. Due to the rising consumption of illicit drugs, organizations are rapidly using DOA testing kits.
As per the 2014 National Survey on Drug Use and Health (NSDUH) in the U.S., 10.0 million people aged 12 years or above were driving after consuming illicit drugs in 2013. The consumption of illicit drugs is rising rapidly, due to which the usage of drug abuse testing is also on the rise, which, in turn, is resulting in the growth of the DOA testing market. As per the World Drug Report by United Nations Office on Drugs and Crime, in 2013, around 203.0 million illicit drug users aged 15 years to 64 years existed in the world, and the number increased to nearly 246.0 million in 2015.
Competitive Analysis
Some of the key players operating in the drug of abuse testing market include Danaher Corporation, Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, Express Diagnostics Int'l, Inc., bioMérieux S.A., Waters Corporation, Roche Holding AG, Quest Diagnostics Inc., Laboratory Corporation of America Holdings, Alere Inc., Abbott Laboratories, Randox Laboratories Ltd., Psychemedics Corporation, Bio-Rad Laboratories, Inc., Sonic Healthcare Ltd., and ThermoFisher Scientific Inc.
Based on product, the drug of abuse testing market is bifurcated into consumable and equipment. Of these, during the historical period (2013–2016), the consumable bifurcation led the market in terms of revenue, and it is predicted to continue leading it during the forecast period. The reason behind the rapid growth of consumables is that these are handy and available for on-site testing for various types of drugs. Consumables include products such as rapid test kits that are used for the testing of illicit drugs.
 |
| To Learn More About this report at: http://bit.ly/36LBl9o |
As per the 2014 National Survey on Drug Use and Health (NSDUH) in the U.S., 10.0 million people aged 12 years or above were driving after consuming illicit drugs in 2013. The consumption of illicit drugs is rising rapidly, due to which the usage of drug abuse testing is also on the rise, which, in turn, is resulting in the growth of the DOA testing market. As per the World Drug Report by United Nations Office on Drugs and Crime, in 2013, around 203.0 million illicit drug users aged 15 years to 64 years existed in the world, and the number increased to nearly 246.0 million in 2015.
Competitive Analysis
Some of the key players operating in the drug of abuse testing market include Danaher Corporation, Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, Express Diagnostics Int'l, Inc., bioMérieux S.A., Waters Corporation, Roche Holding AG, Quest Diagnostics Inc., Laboratory Corporation of America Holdings, Alere Inc., Abbott Laboratories, Randox Laboratories Ltd., Psychemedics Corporation, Bio-Rad Laboratories, Inc., Sonic Healthcare Ltd., and ThermoFisher Scientific Inc.
